Press Release - Company Data

iCo Therapeutics Inc. iCo-007 Program to be Presented & CEO to Sit on Panel at Retinal Physician Symposium 2011
Posted 2011-02-23 11:13TSXV_ICO
is pleased to announce that iCo's President and CEO, Andrew Rae, has been invited to participate in the Early Stage Company Panel at Retinal Physician Symposium 2011 (RPS).

iCo Therapeutics Inc. Completes iCo-007 Phase 2 Clinical Supply Manufacturing
Posted 2011-02-22 11:00TSXV_ICO
today announced the completion of drug product manufacturing activities as part of its Phase 2 clinical program investigating multiple doses and injections of iCo-007 in patients with diabetic macular

iCo Therapeutics Extends Investor Relations Engagement with The Trout Group
Posted 2011-01-18 14:13TSXV_ICO
——VANCOUVER, BRITISH COLUMBIA, Dec 24, 2010 (MARKETWIRE via COMTEX News Network) --

iCo Therapeutics Reports Third Quarter 2010 Financial Results
Posted 2011-01-18 14:11TSXV_ICO
——VANCOUVER, BRITISH COLUMBIA, Nov 26, 2010 (MARKETWIRE via COMTEX News Network) --

iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties
Posted 2010-12-08 09:38TSXV_ICO
today announced that iCo has granted Immune Pharmaceuticals (IMPH), based in Israel and the United States, an option to an exclusive license for the development and commercialization rights to the sys

iCo Therapeutics Selected as Canada's Top 10(TM) Competition Winner
Posted 2010-10-13 13:12TSXV_ICO
is pleased to announce that the company has been selected as one of Canada's Top 10(TM) Competition winners. Top 10(TM) winners are chosen by an independent expert panel of Canadian and U.S.

iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Posted 2010-09-29 09:35TSXV_ICO
is pleased to announce that the Company's oral Amphotericin B program, "iCo-009", has been granted Orphan Drug status for the treatment of Visceral Leishmaniasis (VL) by the US Food and Drug Administr

iCo Therapeutics Appoints Infectious Disease Experts to Scientific Advisory Board
Posted 2010-09-22 08:43TSXV_ICO
is pleased to announce the appointments of Dr. Thomas Walsh, Dr. Coleman Rotstein, and Dr.

iCo Therapeutics Announces Second Quarter 2010 Financial Results
Posted 2010-08-27 15:17TSXV_ICO
today reported operational and financial results for the second quarter ending June 30, 2010.

iCo Therapeutics Announces First Quarter 2010 Financial Results
Posted 2010-05-26 14:42TSXV_ICO
today reported operational and financial results for the first quarter ending March 31, 2010.